Andrew Jeffreys
Family · McKinney, TXNPI 1164457024
Payments from drug & device makers
Across 144 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$253
- Amgen$195
- GSK$150
- Pfizer$140
- AbbVie$114
- Eisai Inc.$106
- plus $2K from 34 others
What the payments were for
- Food & beverage$2,522100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $253 |
| Amgen(2 entities) | 13 | $195 |
| GSK | 9 | $150 |
| Pfizer | 7 | $140 |
| AbbVie | 6 | $114 |
| Eisai Inc. | 5 | $106 |
| AstraZeneca | 6 | $103 |
| Sumitomo Pharma America, Inc. | 5 | $101 |
| Acadia Pharmaceuticals Inc | 6 | $98 |
| Bayer | 5 | $91 |
| Inari Medical, Inc. | 4 | $90 |
| Biogen | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Lundbeck LLC | 4 | $68 |
| Exact Sciences | 4 | $67 |
| Corcept Therapeutics | 3 | $62 |
| Avanir Pharmaceuticals, Inc. | 5 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Kyowa Kirin, Inc. | 2 | $51 |
| Novo Nordisk | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Lilly USA, LLC | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Boehringer Ingelheim | 1 | $29 |
| UCB, Inc. | 1 | $28 |
| Almatica Pharma LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Medtronic | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Inogen, Inc. | 1 | $15 |
| CMP Pharma, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
How this compares
$2,522 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $150,399 |
| EliquisApixaban | 111 | $134,539 |
| JardianceEmpagliflozin | 84 | $93,428 |
| MyrbetriqMirabegron | 92 | $77,059 |
| Dupixent PenDupilumab | 11 | $48,696 |
| JanuviaSitagliptin Phosphate | 44 | $37,455 |
| RybelsusSemaglutide | 24 | $31,775 |
| MounjaroTirzepatide | 19 | $27,843 |
| LinzessLinaclotide | 30 | $27,596 |
| VraylarCariprazine Hcl | 12 | $20,116 |
| EntrestoSacubitril/Valsartan | 15 | $17,990 |
| XareltoRivaroxaban | 15 | $14,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $13,516 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $13,344 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $11,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $48 | $182,175150 claims |
| PfizerEliquis | $140 | $134,539111 claims |
| Boehringer IngelheimJardiance | $29 | $93,42884 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $77,05992 claims |
| AbbVieLinzess, Vraylar, Namzaric | $114 | $59,02656 claims |
| Lilly USA, LLCMounjaro | $40 | $27,84319 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $150 | $26,86033 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $103 | $18,97840 claims |
| NovartisEntresto | $253 | $17,99015 claims |
| Johnson & JohnsonXarelto | $30 | $14,00015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in McKinney
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.